rhASM Dose Escalation for Toxicity-Limited ASMD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for Niemann-Pick disease, particularly type B, face challenges in administering effective doses of acid sphingomyelinase (ASM) due to toxic side effects, even in patients with residual enzyme activity, making it difficult to manage sphingomyelin accumulation and associated clinical symptoms.
Innovation Solution
A dose escalation regimen for recombinant human acid sphingomyelinase (rhASM) is administered in escalating doses, starting with low, non-toxic levels, allowing for gradual substrate debulking and monitoring for adverse effects, followed by maintenance doses based on individual tolerance, ensuring safe and effective enzyme distribution to target organs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of ASM are administered to treat Niemann-Pick disease, then sphingomyelin accumulation is reduced, but toxic side effects occur
Solution Approach 1:
The patent applies preliminary action by administering a low initial dose of ASM (0.025-0.05 mg/kg) before escalating to higher therapeutic doses. This preliminary low-dose administration allows the patient's system to adapt and reduces the risk of toxic side effects when higher doses are eventually administered, thereby resolving the contradiction between treatment effectiveness and toxicity.
Solution Approach 2:
The patent implements dynamics through a dose escalation regimen where the ASM dose is progressively increased from 0.025-0.05 mg/kg to 0.1 mg/kg, then to 0.3 mg/kg, and finally to 0.6-1.0 mg/kg based on patient tolerance. This dynamic dosing approach allows the treatment to adapt to the patient's individual response, maintaining effectiveness while minimizing toxic side effects.
2Productivity
If high doses of ASM are administered to achieve therapeutic effect, then enzyme distribution to target organs is improved, but adverse effects increase
Solution Approach 1:
The patent uses preliminary action by first administering a low dose (0.025-0.05 mg/kg) to assess patient tolerance and baseline response before escalating to higher doses that would achieve optimal enzyme distribution. This preliminary step prevents adverse effects while preserving the ability to reach therapeutic distribution levels subsequently.
Solution Approach 2:
The patent applies feedback through monitoring of adverse effects and sphingomyelin substrate levels at each dose escalation step. Based on this feedback, the dose is adjusted - increasing if tolerated and substrate is reducing, or maintaining/decreasing if adverse effects occur. This feedback mechanism ensures optimal enzyme distribution while minimizing adverse effects.
3Reliability
If dose escalation regimen is used to reduce toxicity, then treatment safety is improved, but treatment duration is extended
Solution Approach 1:
The patent implements dynamics through a flexible dose escalation regimen that adapts to patient response. The treatment progresses through defined dose levels (0.025-0.05, 0.1, 0.3, 0.6-1.0 mg/kg) but allows for individualization based on tolerance and efficacy. This dynamic approach optimizes the balance between safety and treatment duration by avoiding unnecessary delays in patients who tolerate higher doses well.
Solution Approach 2:
The patent uses feedback mechanisms to monitor treatment response and adjust the escalation timeline. By monitoring adverse effects and substrate levels, the treatment can progress more quickly through dose levels when response is favorable, or pause/adjust when issues arise. This feedback-driven approach minimizes unnecessary treatment duration while maintaining safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the safe administration of high doses of ASM, effectively reducing sphingomyelin accumulation in organs while minimizing toxic side effects, thereby improving clinical outcomes in patients with acid sphingomyelinase deficiency.
Implementation Method 1
Acid sphingomyelinase, E.C. 3.1.4.12, (ASM) is a lysosomal phosphodiesterase enzyme that hydrolyzes sphingomyelin, a phospholipid storage substance found in the brain, liver, lungs, spleen and lymph nodes, to ceramide and phosphorylcholine.
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
The invention relates to a recombinant human acid sphingomyelinase (rhASM) for use in a method of treating an acid sphingomyelinase deficiency (ASMD) in a human subject in need thereof, the method comprising administering to the human subject at least one initial dose of 0.025 mg/kg to 0.05 mg/kg of said rhASM; and administering to the human subject an escalating dose regimen at the following sequential doses: (i) 0.1 mg/kg of said rhASM, (ii) 0.3 mg/kg of said rhASM, and (iii) 0.6 mg/kg of said rhASM, wherein each escalating dose is administered at least once before elevating the dose to the next level.